Skip to content

Study · Randomized controlled trial · n = 48 · 1992

7 results

A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding.

Hwang SJ, Lin HC, Chang CF, Lee FY, Lu CW, Hsia HC, Wang SS, Lee SD, Tsai YT, Lo KJ

Journal of hepatology1 Nov 1992Cited by 69 (Europe PMC)

PMID1487608 (opens in a new tab)DOI10.1016/s0168-8278(05)80663-4 (opens in a new tab)PepBankPUB-01487608
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In cirrhotic patients, octreotide controlled variceal bleeding at 6 h in 88% (21/24) versus 54% (13/24) with vasopressin (p = 0.03).

    In plain wordsIn cirrhotic patients, octreotide controlled initial variceal bleeding more often than vasopressin.

    Peptide
    Octreotide
    Outcome
    IncreaseInitial bleeding control at 6 h
    Study

    n = 48

    Comparator
    Vasopressin
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    100 micrograms bolus then 25 micrograms/h · intravenous infusion · 6 hAs given in this study (human).

    Measurements

    Patients with bleeding initially controlled
    88%
    octreotide, after 6 h of infusion
    Patients with bleeding initially controlled
    21 patients
    octreotide, 21/24
    Patients with bleeding initially controlled
    54%
    vasopressin, after 6 h of infusion
    Patients with bleeding initially controlled
    13 patients
    vasopressin, 13/24

    Source sentences

    Summary
    Bleeding was initially controlled after 6 h of drug infusion in 88% (21/24) and 54% (13/24) of the patients treated with octreotide and vasopressin respectively (p = 0.03).
    2 context sentences
    Summary · context
    This randomized controlled trial was conducted to compare the efficacy of intravenous infusion of octreotide (a synthetic long-acting somatostatin analogue) with vasopressin in 48 cirrhotic patients with endoscopically proven bleeding esophageal varices.
    Summary · context
    Twenty-four patients received a continuous infusion of octreotide 25 micrograms/h for 24 h after an initial bolus of 100 micrograms and another 24 patients received a continuous infusion of vasopressin 0.4 U/min for 24 h.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In cirrhotic patients, complete bleeding control at 24 h occurred in 63% (15) with octreotide versus 46% (11) with vasopressin (p > 0.05).

    In plain wordsIn cirrhotic patients, complete bleeding control was numerically higher with octreotide than vasopressin, without statistical significance.

    Peptide
    Octreotide
    Outcome
    IncreaseComplete bleeding control at 24 h
    Study

    n = 48

    Comparator
    Vasopressin
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    100 micrograms bolus then 25 micrograms/h · intravenous infusion · 24 hAs given in this study (human).

    Measurements

    Patients with complete bleeding control
    63%
    octreotide, after 24 h of infusion
    Patients with complete bleeding control
    15 patients
    octreotide
    Patients with complete bleeding control
    46%
    vasopressin, after 24 h of infusion
    Patients with complete bleeding control
    11 patients
    vasopressin

    Source sentences

    Summary
    Complete control of bleeding after 24 h of drug infusion was achieved in 15 (63%) patients receiving octreotide and in 11 (46%) patients receiving vasopressin (p > 0.05).
    2 context sentences
    Summary · context
    This randomized controlled trial was conducted to compare the efficacy of intravenous infusion of octreotide (a synthetic long-acting somatostatin analogue) with vasopressin in 48 cirrhotic patients with endoscopically proven bleeding esophageal varices.
    Summary · context
    Twenty-four patients received a continuous infusion of octreotide 25 micrograms/h for 24 h after an initial bolus of 100 micrograms and another 24 patients received a continuous infusion of vasopressin 0.4 U/min for 24 h.
  3. 03HumanRandomized controlled trialSafety outcome

    In cirrhotic patients, infusion side effects including headache, chest pain and abdominal pain affected 3/24 with octreotide versus 11/24 with vasopressin, significantly fewer.

    In plain wordsIn cirrhotic patients, infusion side effects were less frequent with octreotide than vasopressin.

    Peptide
    Octreotide
    Outcome
    DecreaseInfusion side effects
    Study

    n = 48

    Comparator
    Vasopressin
    Outcome group
    Adverse events · Whole body
    Studied dose
    100 micrograms bolus then 25 micrograms/h · intravenous infusion · 24 hAs given in this study (human).

    Measurements

    Patients with infusion side effects
    3 patients
    octreotide group, 3/24
    Patients with infusion side effects
    11 patients
    vasopressin group, 11/24

    Source sentences

    Summary
    Side effects during drug infusion such as headache, chest pain and abdominal pain were significantly lower in the octreotide group (3/24) than in the vasopressin group (11/24).
    2 context sentences
    Summary · context
    This randomized controlled trial was conducted to compare the efficacy of intravenous infusion of octreotide (a synthetic long-acting somatostatin analogue) with vasopressin in 48 cirrhotic patients with endoscopically proven bleeding esophageal varices.
    Summary · context
    Twenty-four patients received a continuous infusion of octreotide 25 micrograms/h for 24 h after an initial bolus of 100 micrograms and another 24 patients received a continuous infusion of vasopressin 0.4 U/min for 24 h.
  4. 04HumanRandomized controlled trialSafety outcome

    In cirrhotic patients, mortality related to esophageal variceal bleeding did not differ between octreotide and vasopressin.

    In plain wordsIn cirrhotic patients, bleeding-related mortality did not differ between octreotide and vasopressin.

    Peptide
    Octreotide
    Outcome
    No significant changeBleeding-related mortality
    Study

    n = 48

    Comparator
    Vasopressin
    Outcome group
    Mortality · Gastrointestinal
    Studied dose
    100 micrograms bolus then 25 micrograms/h · intravenous infusion · 24 hAs given in this study (human).

    Source sentences

    Summary
    Mortality related to bleeding esophageal varices was no different between the two groups.
    2 context sentences
    Summary · context
    This randomized controlled trial was conducted to compare the efficacy of intravenous infusion of octreotide (a synthetic long-acting somatostatin analogue) with vasopressin in 48 cirrhotic patients with endoscopically proven bleeding esophageal varices.
    Summary · context
    Twenty-four patients received a continuous infusion of octreotide 25 micrograms/h for 24 h after an initial bolus of 100 micrograms and another 24 patients received a continuous infusion of vasopressin 0.4 U/min for 24 h.
  5. 05HumanNon-randomized trialEfficacy outcome

    In cirrhotic patients, serum gastrin fell significantly following octreotide infusion.

    In plain wordsIn cirrhotic patients, serum gastrin decreased significantly after octreotide infusion.

    Peptide
    Octreotide
    Outcome
    DecreaseSerum gastrin
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    100 micrograms bolus then 25 micrograms/h · intravenous infusion · 24 hAs given in this study (human).

    Source sentences

    Summary
    Serum gastrin and insulin levels fell significantly following octreotide infusion, but plasma glucose levels remained unchanged.
    2 context sentences
    Summary · context
    This randomized controlled trial was conducted to compare the efficacy of intravenous infusion of octreotide (a synthetic long-acting somatostatin analogue) with vasopressin in 48 cirrhotic patients with endoscopically proven bleeding esophageal varices.
    Summary · context
    Twenty-four patients received a continuous infusion of octreotide 25 micrograms/h for 24 h after an initial bolus of 100 micrograms and another 24 patients received a continuous infusion of vasopressin 0.4 U/min for 24 h.
  6. 06HumanNon-randomized trialEfficacy outcome

    In cirrhotic patients, serum insulin fell significantly following octreotide infusion.

    In plain wordsIn cirrhotic patients, serum insulin decreased significantly after octreotide infusion.

    Peptide
    Octreotide
    Outcome
    DecreaseSerum insulin
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    100 micrograms bolus then 25 micrograms/h · intravenous infusion · 24 hAs given in this study (human).

    Source sentences

    Summary
    Serum gastrin and insulin levels fell significantly following octreotide infusion, but plasma glucose levels remained unchanged.
    2 context sentences
    Summary · context
    This randomized controlled trial was conducted to compare the efficacy of intravenous infusion of octreotide (a synthetic long-acting somatostatin analogue) with vasopressin in 48 cirrhotic patients with endoscopically proven bleeding esophageal varices.
    Summary · context
    Twenty-four patients received a continuous infusion of octreotide 25 micrograms/h for 24 h after an initial bolus of 100 micrograms and another 24 patients received a continuous infusion of vasopressin 0.4 U/min for 24 h.
  7. 07HumanNon-randomized trialEfficacy outcome

    In cirrhotic patients, plasma glucose remained unchanged following octreotide infusion.

    In plain wordsIn cirrhotic patients, plasma glucose did not change after octreotide infusion.

    Peptide
    Octreotide
    Outcome
    No significant changePlasma glucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 micrograms bolus then 25 micrograms/h · intravenous infusion · 24 hAs given in this study (human).

    Source sentences

    Summary
    Serum gastrin and insulin levels fell significantly following octreotide infusion, but plasma glucose levels remained unchanged.
    2 context sentences
    Summary · context
    This randomized controlled trial was conducted to compare the efficacy of intravenous infusion of octreotide (a synthetic long-acting somatostatin analogue) with vasopressin in 48 cirrhotic patients with endoscopically proven bleeding esophageal varices.
    Summary · context
    Twenty-four patients received a continuous infusion of octreotide 25 micrograms/h for 24 h after an initial bolus of 100 micrograms and another 24 patients received a continuous infusion of vasopressin 0.4 U/min for 24 h.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.